Palo Alto, California-based drug delivery systems company increases size of planned offering of "liquid yield option" notes, or LYONs, due Dec. 21, 2010 from $600 mil. to $750 mil. Each LYON is being offered at a price of $229.34 per $1,000 principal amount at maturity. Merrill Lynch is underwriting the offering. Alza will net approximately $166.4 mil., which will be used for general corporate purposes.
You may also be interested in...
Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.